Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration

Hari K. Narayan, Karyn Sheline, Victor Wong, Dennis Kuo, Sun Choo, Janet Yoon, Kasey Leger, Shelby Kutty, Michael Fradley, Adriana Tremoulet, Bonnie Ky, Saro Armenian, Avirup Guha

Research output: Contribution to journalArticlepeer-review

Abstract

We sought to examine cardiovascular toxicities associated with tyrosine kinase inhibitors in pediatrics. We examined 1624 pediatric adverse events with imatinib, dasatinib, sorafenib, pazopanib, crizotinib, and ruxolitinib reported to the Food and Drug Administration between January 1, 2015, and August 14, 2020. There were 102 cardiovascular event reports. Hypertension was the most commonly reported cardiovascular event and was most frequently associated with sorafenib and pazopanib. The presence of infection increased the reporting odds of cardiovascular events overall and specifically cardiac arrest, heart failure, and hypertension. These data provide early insight into cardiovascular toxicities with tyrosine kinase inhibitor use in pediatrics.

Original languageEnglish (US)
Article numbere30059
JournalPediatric Blood and Cancer
Volume70
Issue number2
DOIs
StatePublished - Feb 2023

Keywords

  • cardiotoxicity
  • hypertension
  • pediatric cancer
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration'. Together they form a unique fingerprint.

Cite this